MAX and ganglioneuroma: This suggests that all MAX germline mutation carriers should receive a comprehensive baseline assessment of the diversity of neurocrest-derived diseases, such as PPGL, PA, hyperparathyroidism, and ganglioneuroma/neuroblastoma.